This report covers summary information of the in-depth paid report available at goodinvestory.com. The concept behind this report is to keep the report simple, understandable and actionable to make money for you. We use use short paragraphs, symbols, figures and depictions to illustrate the attractiveness of the stock. You can make your decision based on 2 minute scan of this report.

1. Stock Ticker : PSDV
Exchange : NasdaqGM
Sector : Drug Manufacturers - Major
Report date : Fri May 09 07:58:20 EDT 2014
Industry overview
Market Cap
Market Cap is the price of
all the outstanding
common shares if we were
to buy it all at the current
price
96.29M
The benchmark company
(Pfizer) in the drug
manufacturers - major
sector is 204500 times the
size of pSivida Corp.
Ultra Small Caps are a
choice for people who can
handle very high
volatility/risk with very low
liquidity
1

2. Stock Analysis
Growth Analysis
Companies that have grown historically are more likely to exibit similar growth in the future. Read
the trends in the 4 year annualized profit growth, book value growth and sales growth shown
below:
How good are the returns?
RoE is the speed at which the company might grow without sorting to additional fund raising.
RoA gives an idea as to how efficient management is at using its assets to generate earnings.
The 2-year and 4-year values give a reasonable assurance about the growth sustenance.
KEY
KEY
2

3. Piotroski Score
Seperate Winners from Losers
The Piotroski scoring system is a nine point system to determine the strength of a firm's financial
position. The score was developed by an accounting professor out of Chicago named Joseph
Piotroski. If it scores an 8 or 9, then the fundamentals are great for the stock.
Score: 4/9
3

4. DISCLAIMER
This report is prepared by the good.inve.story. software and is not prepared by an
actual person who has a CFA or any other certification.
good.inve.story. is still in BETA mode. So, please let us know if you find any errors.
We would love to hear from you.
This report is based on information obtained from public sources and sources
believed to be reliable, but no independent verification has been made nor is its
accuracy or completeness guaranteed.
This report is not an advisory to buy or sell. Please buy only if you think, this is the
right company at the right price and sell only if you don’t see any potential for
upside.
get more @ goodinvestory.com
4